Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Preliminary finding of stable disease in two...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”...
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort...
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to...
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...
AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update Company continues progress across Ampligen® clinical development programs Growing...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.02 | 9.70873786408 | 0.206 | 0.226 | 0.2 | 1385 | 0.21256331 | DE |
| 4 | -0.02 | -8.13008130081 | 0.246 | 0.246 | 0.178 | 8749 | 0.20729914 | DE |
| 12 | -0.0559999 | -19.8581276093 | 0.2819999 | 0.31 | 0.178 | 7984 | 0.23531086 | DE |
| 26 | -0.13 | -36.5168539326 | 0.356 | 0.436 | 0.178 | 5084 | 0.25695784 | DE |
| 52 | -0.22 | -49.3273542601 | 0.446 | 0.6 | 0.178 | 3984 | 0.32737932 | DE |
| 156 | -0.3389999 | -59.9999929204 | 0.5649999 | 0.61 | 0.178 | 3932 | 0.34623229 | DE |
| 260 | -0.3389999 | -59.9999929204 | 0.5649999 | 0.61 | 0.178 | 3932 | 0.34623229 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
